I am trained as both an Infectious Disease specialist and as an expert in innate defense against bacterial infection, with a focus on Gram-negative organisms.聽 As an Infectious Disease specialist, I am particularly interested in treatment approaches to multidrug-resistant Gram-negative infections.聽 As a researcher, I study the innate defenses against these types of infections.聽 In one project, I study the Bactericidal/Permeability-Increasing protein (BPI) - an endogenous antibiotic found in neutrophils and available in recombinant form. BPI has potent activity against Gram-negative bacteria, including multidrug-resistant clinical isolates I collect.
I have also studied emerging infections, such as chikungunya, Zika and seasonal influenza. I was engaged in two NIH-sponsored clinical trials for the treatment of seasonal influenza with immune plasma and triple therapy (ribivirin, oseltamivir and amantadine). I was the Principal Investigator for UF site of the NIH-sponsored Adaptive COVID-19 Treatment Trials (ACTT), which identified remdesivir and baricitinib as important agents for the treatment of COVID patients. Most recently, I am the Principal Investigator for the UF site of the STOMP monkeypox clinical trial, and for the Accelerating COVID-19 Therapeutic Interventions and Vaccines clinical trials (ACTIV4a and ACTIV4d).
A5418 is a randomized, placebo-controlled, double-blind study to establish the efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV disease.
This is a placebo-controlled study to evaluate the addition of CAL02 to standard of care in treating hospitalized subjects diagnosed with severe community acquired bacterial pneumonia (SCABP) requiring critical care measures
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an鈥�
45 publications
2025
Journal of critical care
鈥�2024
International journal of STD & AIDS
鈥�2024
JAMA network open
鈥�2024
Pharmacotherapy
鈥�2023
JAMA network open
鈥�